Business Context and Reporting Period
Company: Processa Pharmaceuticals, Inc. (PCSA)
Filing Type: Form 8-K (Current Report)
Date of Report: May 24, 2023
Context: The filing discloses regulatory and investor relations activities, specifically Dr. David Young's participation in the World Orphan Drug Congress in Washington, DC. The company is incorporated in Delaware and trades on the Nasdaq Capital Market.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on event disclosure rather than financial performance data.
Material Changes
No material changes to financial position or operations are reported in this document. The filing serves to announce upcoming corporate presentations.
Guidance, Outlook, and Management Commentary
- Upcoming Presentations: Dr. David Young, CEO, is scheduled to present on May 24, 2023, at the World Orphan Drug Congress.
- Session 1: "Clinical Development & Regulatory Panel Session: Patient focused drug development – best practices on patient group and drug developer interaction with FDA" at 4:20 PM ET.
- Session 2: "Applying FDA's Project Optimus to the Next Generation of Chemotherapy Drugs Treating Rare Cancers" at 1:00 PM ET in Theater 6.
- Availability: Presentation materials are furnished as Exhibit 99.1 and will be available on the company's website under the "Investors" section.
- Forward-Looking Statements: The company undertakes no duty to update or revise the information contained in this report, though it may do so via future filings or press releases.
Key Facts for Investor Verification
- Verify the content of the presentation materials attached as Exhibit 99.1 regarding FDA's Project Optimus and rare cancer treatments.
- Confirm the company's cash runway and funding status in the most recent 10-Q or 10-K, as this 8-K contains no financial data.
- Monitor the company website for updates following the May 24, 2023, presentations.